<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03366298</url>
  </required_header>
  <id_info>
    <org_study_id>17SM4137</org_study_id>
    <secondary_id>2017-003239-13</secondary_id>
    <secondary_id>232931</secondary_id>
    <nct_id>NCT03366298</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Intramuscular Adrenaline in Food--Allergic Teenagers</brief_title>
  <acronym>PIMAT</acronym>
  <official_title>Pharmacokinetics of Intramuscular Adrenaline in Food--Allergic Teenagers: Does Dose Matter?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Food allergy affects up to 2% of adults and 8% of children in the United Kingdom (UK), and is&#xD;
      a major public health issue. It is the commonest cause of life-threatening allergic reactions&#xD;
      (anaphylaxis), which can be fatal. Adrenaline (epinephrine) auto-injector (AAI) devices are&#xD;
      the first-line treatment for anaphylaxis, yet in a UK survey, over 80% of 245 teenagers&#xD;
      experiencing anaphylaxis did not use their AAI. Delays in, or lack of adrenaline&#xD;
      (epinephrine) administration during anaphylaxis are risk factors for fatal anaphylaxis.&#xD;
&#xD;
      In 2010, a coroner's investigation into the death of a food-allergic teenager in the UK&#xD;
      raised several questions around AAI safety and efficacy, since the teenager died despite&#xD;
      administering her auto-injector device. This prompted a review by the Medicines and&#xD;
      Healthcare products Regulatory Agency (MHRA) in 2014 into the clinical and quality&#xD;
      considerations of AAIs. Two recommendations which came from the review was that companies&#xD;
      'should be encouraged to develop a 0.5mg [dose] AAI.' In the UK currently only Emerade, one&#xD;
      of the three companies selling AAIs, manufactures a 0.5mg (500mcg) version. Emerade also has&#xD;
      a longer needle length (23mm) compared to other AAIs (typically 15mm).&#xD;
&#xD;
      The investigators plan to formally assess the pharmacokinetics (PK) and pharmacodynamics (PD)&#xD;
      of self-injection with intramuscular adrenaline (epinephrine) in teenagers at risk of&#xD;
      anaphylaxis due to food allergy, and have been prescribed AAI.&#xD;
&#xD;
        1. The investigators will compare self-injection with 300mcg vs 500mcg in teenagers of body&#xD;
           weight &gt;40kg. In a 40kg person, an adrenaline dose of 300mcg results in an effective&#xD;
           UNDER-dosing of 30% by body weight.&#xD;
&#xD;
        2. The investigators will also assess the impact of needle length on injection, by&#xD;
           comparing two different devices, both of which deliver 300mcg, but one via a 15mm needle&#xD;
           and the other with a 23mm needle.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 24, 2017</start_date>
  <completion_date type="Actual">October 2, 2018</completion_date>
  <primary_completion_date type="Actual">October 2, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Catecholamine Levels (Maximum Concentration, Cmax)</measure>
    <time_frame>3 hours</time_frame>
    <description>Pharmacokinetics (plasma catecholamine levels: Cmax) following intramuscular self-injection of 300mcg and 500mcg adrenaline using an auto-injector device, in food-allergic teenagers over 40kg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Catecholamine Levels (Time to Maximum Concentration, Tmax)</measure>
    <time_frame>3 hours</time_frame>
    <description>Pharmacokinetics (plasma catecholamine levels: Tmax) following intramuscular self-injection of 300mcg and 500mcg adrenaline using an auto-injector device, in food-allergic teenagers over 40kg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Catecholamine Levels (Maximum Concentration, Area-under-curve (AUC))</measure>
    <time_frame>3 hours</time_frame>
    <description>Pharmacokinetics (plasma catecholamine levels: AUC) following intramuscular self-injection of 300mcg and 500mcg adrenaline using an auto-injector device, in food-allergic teenagers over 40kg.&#xD;
Baseline corrected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Heart Rate Following Self-injection of Adrenaline (300mcg, 500mcg) on Separate Occasions.</measure>
    <time_frame>3 hours</time_frame>
    <description>Pharmacodynamics (heart rate) following intramuscular self-injection of 300mcg and 500mcg adrenaline using an auto-injector device, in food-allergic teenagers over 40kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Pressure Following Self-injection of Adrenaline (300mcg, 500mcg) on Separate Occasions.</measure>
    <time_frame>3 hours</time_frame>
    <description>Pharmacodynamics (blood pressure) following intramuscular self-injection of 300mcg and 500mcg adrenaline using an auto-injector device, in food-allergic teenagers over 40kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Stroke Volume Following Self-injection of Adrenaline (300mcg, 500mcg) on Separate Occasions.</measure>
    <time_frame>3 hours</time_frame>
    <description>Pharmacodynamics (stroke volume) following intramuscular self-injection of 300mcg and 500mcg adrenaline using an auto-injector device, in food-allergic teenagers over 40kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Needle Length on Pharmacokinetics (Plasma Catecholamine Levels: Cmax)</measure>
    <time_frame>3 hours</time_frame>
    <description>Pharmacokinetics (plasma catecholamine levels: Cmax) following intramuscular self-injection of 300mcg adrenaline using two auto-injector devices with different needle lengths (15mm vs 23mm), in food-allergic teenagers over 40kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Needle Length on Pharmacokinetics (Plasma Catecholamine Levels: Tmax)</measure>
    <time_frame>3 hours</time_frame>
    <description>Pharmacokinetics (plasma catecholamine levels: Tmax) following intramuscular self-injection of 300mcg adrenaline using two auto-injector devices with different needle lengths (15mm vs 23mm), in food-allergic teenagers over 40kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Needle Length on Pharmacokinetics (Plasma Catecholamine Levels: AUC)</measure>
    <time_frame>3 hours</time_frame>
    <description>Pharmacokinetics (plasma catecholamine levels: AUC) following intramuscular self-injection of 300mcg adrenaline using two auto-injector devices with different needle lengths (15mm vs 23mm), in food-allergic teenagers over 40kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Needle Length on Pharmacodynamics (Cardiovascular Parameters: Heart Rate)</measure>
    <time_frame>3 hours</time_frame>
    <description>The pharmacodynamics (cardiovascular parameters: heart rate) following intramuscular self-injection of 300mcg adrenaline using two auto-injector devices with different needle lengths (15mm vs 23mm), in food-allergic teenagers over 40kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Needle Length on Pharmacodynamics (Cardiovascular Parameters: Blood Pressure)</measure>
    <time_frame>3 hours</time_frame>
    <description>The pharmacodynamics (cardiovascular parameters: blood pressure) following intramuscular self-injection of 300mcg adrenaline using two auto-injector devices with different needle lengths (15mm vs 23mm), in food-allergic teenagers over 40kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Needle Length on Pharmacodynamics (Cardiovascular Parameters: Stroke Volume)</measure>
    <time_frame>3 hours</time_frame>
    <description>The pharmacodynamics (cardiovascular parameters: stroke volume) following intramuscular self-injection of 300mcg adrenaline using two auto-injector devices with different needle lengths (15mm vs 23mm), in food-allergic teenagers over 40kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events Following Self-administration of Adrenaline Via Autoinjector Device</measure>
    <time_frame>1 day</time_frame>
    <description>Adverse events following self-administration of adrenaline via autoinjector device defined as in protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Health-related Quality of Life (HRQL) as Measured Using FAQLQ</measure>
    <time_frame>1 month</time_frame>
    <description>The impact of self-administration of adrenaline autoinjectors (in a non-reaction setting) on health-related quality of life (HRQL) measures in food-allergic teenagers and their parents.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Anaphylaxis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Visit 1: Emerade 300mcg then Epipen 0.3mg Visit 2: Emerade 500mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Visit 1: Epipen 0.3mg then Emerade 300mcg Visit 2: Emerade 500mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Visit 1: Emerade 500mcg Visit 2: Emerade 300mcg then Epipen 0.3mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Visit 1: Emerade 500mcg Visit 2: Epipen 0.3mg then Emerade 300mcg</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Epipen 0.3mg</intervention_name>
    <description>Epipen 0.3mg auto-injector</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>Epinephrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Emerade 300mcg</intervention_name>
    <description>Emerade 300mcg auto-injector</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>Epinephrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Emerade 500mcg</intervention_name>
    <description>Emerade 500mcg auto-injector</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>Epinephrine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 13 - 18 years inclusive&#xD;
&#xD;
          -  Body mass &gt;40kg&#xD;
&#xD;
          -  Prescription of AAI due to physician diagnosis of Immunoglobulin E-mediated food&#xD;
             allergy.&#xD;
&#xD;
          -  Written informed consent from parent/guardian together with patient assent, for&#xD;
             participants under 16 years of age. For young people age 16+ years, consent will be&#xD;
             obtained from the participant themselves.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known cardiac comorbidity (including hypertension, structural or electrophysiological&#xD;
             diagnoses) or prescribed a medicine to control cardiovascular disease/hypertension.&#xD;
&#xD;
          -  Known endocrine or renal disease&#xD;
&#xD;
          -  Poorly controlled asthma requiring daily rescue treatment with a bronchodilator.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Unwilling or unable to comply with study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul J Turner, FRACP PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imperial College London / Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 21, 2017</study_first_submitted>
  <study_first_submitted_qc>December 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2017</study_first_posted>
  <results_first_submitted>March 9, 2021</results_first_submitted>
  <results_first_submitted_qc>March 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 5, 2021</results_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Imperial College London</investigator_affiliation>
    <investigator_full_name>Paul Turner</investigator_full_name>
    <investigator_title>MRC Clinician Scientist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anaphylaxis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT03366298/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Emerade 300 / Epipen 0.3mg / Emerade 500</title>
          <description>Visit 1: Emerade 300mcg then Epipen 0.3mg Visit 2: Emerade 500mcg&#xD;
Epipen 0.3mg: Epipen 0.3mg auto-injector&#xD;
Emerade 300mcg: Emerade 300mcg auto-injector&#xD;
Emerade 500mcg: Emerade 500mcg auto-injector</description>
        </group>
        <group group_id="P2">
          <title>Epipen 0.3mg / Emerade 300 / Emerade 500</title>
          <description>Visit 1: Epipen 0.3mg then Emerade 300mcg Visit 2: Emerade 500mcg&#xD;
Epipen 0.3mg: Epipen 0.3mg auto-injector&#xD;
Emerade 300mcg: Emerade 300mcg auto-injector&#xD;
Emerade 500mcg: Emerade 500mcg auto-injector</description>
        </group>
        <group group_id="P3">
          <title>Emerade 500 / Emerade 300 / Epipen 0.3mg</title>
          <description>Visit 1: Emerade 500mcg Visit 2: Emerade 300mcg then Epipen 0.3mg&#xD;
Epipen 0.3mg: Epipen 0.3mg auto-injector&#xD;
Emerade 300mcg: Emerade 300mcg auto-injector&#xD;
Emerade 500mcg: Emerade 500mcg auto-injector</description>
        </group>
        <group group_id="P4">
          <title>Emerade 500 / Epipen 0.3mg / Emerade 300</title>
          <description>Visit 1: Emerade 500mcg Visit 2: Epipen 0.3mg then Emerade 300mcg&#xD;
Epipen 0.3mg: Epipen 0.3mg auto-injector&#xD;
Emerade 300mcg: Emerade 300mcg auto-injector&#xD;
Emerade 500mcg: Emerade 500mcg auto-injector</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Cohort</title>
          <description>Overall study cohort</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.4" lower_limit="13.3" upper_limit="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" lower_limit="16.1" upper_limit="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Catecholamine Levels (Maximum Concentration, Cmax)</title>
        <description>Pharmacokinetics (plasma catecholamine levels: Cmax) following intramuscular self-injection of 300mcg and 500mcg adrenaline using an auto-injector device, in food-allergic teenagers over 40kg.</description>
        <time_frame>3 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Emerade 300mcg Injection</title>
            <description>Self-injection with Emerade 300mcg adrenaline auto-injector</description>
          </group>
          <group group_id="O2">
            <title>Emerade 500mcg Injection</title>
            <description>Self-injection with Emerade 500mcg adrenaline auto-injector</description>
          </group>
          <group group_id="O3">
            <title>Epipen 0.3mg</title>
            <description>Self-injection with Epipen 0.3mg adrenaline auto-injector</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Catecholamine Levels (Maximum Concentration, Cmax)</title>
          <description>Pharmacokinetics (plasma catecholamine levels: Cmax) following intramuscular self-injection of 300mcg and 500mcg adrenaline using an auto-injector device, in food-allergic teenagers over 40kg.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218" lower_limit="132" upper_limit="359"/>
                    <measurement group_id="O2" value="394" lower_limit="310" upper_limit="500"/>
                    <measurement group_id="O3" value="290" lower_limit="200" upper_limit="421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Catecholamine Levels (Time to Maximum Concentration, Tmax)</title>
        <description>Pharmacokinetics (plasma catecholamine levels: Tmax) following intramuscular self-injection of 300mcg and 500mcg adrenaline using an auto-injector device, in food-allergic teenagers over 40kg.</description>
        <time_frame>3 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Emerade 300mcg Injection</title>
            <description>Self-injection with Emerade 300mcg adrenaline auto-injector</description>
          </group>
          <group group_id="O2">
            <title>Emerade 500mcg Injection</title>
            <description>Self-injection with Emerade 500mcg adrenaline auto-injector</description>
          </group>
          <group group_id="O3">
            <title>Epipen 0.3mg</title>
            <description>Self-injection with Epipen 0.3mg adrenaline auto-injector</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Catecholamine Levels (Time to Maximum Concentration, Tmax)</title>
          <description>Pharmacokinetics (plasma catecholamine levels: Tmax) following intramuscular self-injection of 300mcg and 500mcg adrenaline using an auto-injector device, in food-allergic teenagers over 40kg.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" lower_limit="5.3" upper_limit="17.4"/>
                    <measurement group_id="O2" value="8.5" lower_limit="6.1" upper_limit="11.8"/>
                    <measurement group_id="O3" value="5.9" lower_limit="4.9" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Catecholamine Levels (Maximum Concentration, Area-under-curve (AUC))</title>
        <description>Pharmacokinetics (plasma catecholamine levels: AUC) following intramuscular self-injection of 300mcg and 500mcg adrenaline using an auto-injector device, in food-allergic teenagers over 40kg.&#xD;
Baseline corrected.</description>
        <time_frame>3 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Emerade 300mcg Injection</title>
            <description>Self-injection with Emerade 300mcg adrenaline auto-injector</description>
          </group>
          <group group_id="O2">
            <title>Emerade 500mcg Injection</title>
            <description>Self-injection with Emerade 500mcg adrenaline auto-injector</description>
          </group>
          <group group_id="O3">
            <title>Epipen 0.3mg</title>
            <description>Self-injection with Epipen 0.3mg adrenaline auto-injector</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Catecholamine Levels (Maximum Concentration, Area-under-curve (AUC))</title>
          <description>Pharmacokinetics (plasma catecholamine levels: AUC) following intramuscular self-injection of 300mcg and 500mcg adrenaline using an auto-injector device, in food-allergic teenagers over 40kg.&#xD;
Baseline corrected.</description>
          <units>hr.pg/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174" lower_limit="86" upper_limit="354"/>
                    <measurement group_id="O2" value="387" lower_limit="263" upper_limit="570"/>
                    <measurement group_id="O3" value="203" lower_limit="142" upper_limit="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Heart Rate Following Self-injection of Adrenaline (300mcg, 500mcg) on Separate Occasions.</title>
        <description>Pharmacodynamics (heart rate) following intramuscular self-injection of 300mcg and 500mcg adrenaline using an auto-injector device, in food-allergic teenagers over 40kg.</description>
        <time_frame>3 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Pressure Following Self-injection of Adrenaline (300mcg, 500mcg) on Separate Occasions.</title>
        <description>Pharmacodynamics (blood pressure) following intramuscular self-injection of 300mcg and 500mcg adrenaline using an auto-injector device, in food-allergic teenagers over 40kg.</description>
        <time_frame>3 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Stroke Volume Following Self-injection of Adrenaline (300mcg, 500mcg) on Separate Occasions.</title>
        <description>Pharmacodynamics (stroke volume) following intramuscular self-injection of 300mcg and 500mcg adrenaline using an auto-injector device, in food-allergic teenagers over 40kg.</description>
        <time_frame>3 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Needle Length on Pharmacokinetics (Plasma Catecholamine Levels: Cmax)</title>
        <description>Pharmacokinetics (plasma catecholamine levels: Cmax) following intramuscular self-injection of 300mcg adrenaline using two auto-injector devices with different needle lengths (15mm vs 23mm), in food-allergic teenagers over 40kg.</description>
        <time_frame>3 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Needle Length on Pharmacokinetics (Plasma Catecholamine Levels: Tmax)</title>
        <description>Pharmacokinetics (plasma catecholamine levels: Tmax) following intramuscular self-injection of 300mcg adrenaline using two auto-injector devices with different needle lengths (15mm vs 23mm), in food-allergic teenagers over 40kg.</description>
        <time_frame>3 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Needle Length on Pharmacokinetics (Plasma Catecholamine Levels: AUC)</title>
        <description>Pharmacokinetics (plasma catecholamine levels: AUC) following intramuscular self-injection of 300mcg adrenaline using two auto-injector devices with different needle lengths (15mm vs 23mm), in food-allergic teenagers over 40kg.</description>
        <time_frame>3 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Needle Length on Pharmacodynamics (Cardiovascular Parameters: Heart Rate)</title>
        <description>The pharmacodynamics (cardiovascular parameters: heart rate) following intramuscular self-injection of 300mcg adrenaline using two auto-injector devices with different needle lengths (15mm vs 23mm), in food-allergic teenagers over 40kg.</description>
        <time_frame>3 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Needle Length on Pharmacodynamics (Cardiovascular Parameters: Blood Pressure)</title>
        <description>The pharmacodynamics (cardiovascular parameters: blood pressure) following intramuscular self-injection of 300mcg adrenaline using two auto-injector devices with different needle lengths (15mm vs 23mm), in food-allergic teenagers over 40kg.</description>
        <time_frame>3 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Needle Length on Pharmacodynamics (Cardiovascular Parameters: Stroke Volume)</title>
        <description>The pharmacodynamics (cardiovascular parameters: stroke volume) following intramuscular self-injection of 300mcg adrenaline using two auto-injector devices with different needle lengths (15mm vs 23mm), in food-allergic teenagers over 40kg.</description>
        <time_frame>3 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events Following Self-administration of Adrenaline Via Autoinjector Device</title>
        <description>Adverse events following self-administration of adrenaline via autoinjector device defined as in protocol</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Emerade 300mcg Injection</title>
            <description>Self-injection with Emerade 300mcg adrenaline auto-injector</description>
          </group>
          <group group_id="O2">
            <title>Emerade 500mcg Injection</title>
            <description>Self-injection with Emerade 500mcg adrenaline auto-injector</description>
          </group>
          <group group_id="O3">
            <title>Epipen 0.3mg</title>
            <description>Self-injection with Epipen 0.3mg adrenaline auto-injector</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events Following Self-administration of Adrenaline Via Autoinjector Device</title>
          <description>Adverse events following self-administration of adrenaline via autoinjector device defined as in protocol</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic AE (any)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Palpitations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tremor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Health-related Quality of Life (HRQL) as Measured Using FAQLQ</title>
        <description>The impact of self-administration of adrenaline autoinjectors (in a non-reaction setting) on health-related quality of life (HRQL) measures in food-allergic teenagers and their parents.</description>
        <time_frame>1 month</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Within 24h of injection</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Emerade 300mcg Injection</title>
          <description>Self-injection with Emerade 300mcg adrenaline auto-injector</description>
        </group>
        <group group_id="E2">
          <title>Emerade 500mcg Injection</title>
          <description>Self-injection with Emerade 500mcg adrenaline auto-injector</description>
        </group>
        <group group_id="E3">
          <title>Epipen 0.3mg</title>
          <description>Self-injection with Epipen 0.3mg adrenaline auto-injector</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Paul Turner</name_or_title>
      <organization>Imperial College London</organization>
      <phone>+44 20 3312 7754</phone>
      <email>p.turner@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

